In recent years, the tobacco industry has undergone a significant transformation, driven by innovation and shifting consumer preferences. One of the most notable developments is the emergence of IQOS, a heat-not-burn (HNB) tobacco product developed by Philip Morris International. Unlike traditional cigarettes that burn tobacco, IQOS heats it to a controlled temperature, releasing a nicotine-containing aerosol without combustion. This subtle shift in technology has sparked global debate over its health implications, regulatory challenges, and market potential.
What Is IQOS?
IQOS stands for “I Quit Ordinary Smoking,” though the acronym is not officially defined by the manufacturer. The device consists of two main components: a holder and a charger. Users insert a specially designed tobacco stick, known as a HEETS or HeatStick, into the holder. The device then heats the tobacco to around 350°C—significantly lower than the 600–900°C typical of burning cigarettes. This process produces a vapor that contains nicotine and flavor, but fewer harmful chemicals than cigarette smoke.
Global Expansion and Market Reach
Since its initial launch in Japan and Italy in 2014, IQOS has expanded to over 60 countries, including major markets like Russia, Ukraine, and South Korea. Its popularity is particularly strong in regions with strict anti-smoking laws and high cigarette taxes. In many cases, IQOS is marketed as a “cleaner” alternative to smoking, with less odor, ash, and secondhand smoke.
Philip Morris International has invested billions in research and development, positioning IQOS as part of its vision for a “smoke-free future.” The company claims that millions of smokers have switched to IQOS, and in some markets, it has overtaken traditional cigarette sales.
Health Implications: Safer or Just Different?
The central question surrounding IQOS is whether it’s truly safer than smoking. Independent studies have shown that IQOS emits lower levels of harmful chemicals like carbonyls and volatile organic compounds compared to conventional cigarettes. However, it still delivers nicotine—a highly addictive substance—and some toxicants remain present in the aerosol.
A 2019 review published in the Turkish Journal of Pharmaceutical Sciences highlighted that while IQOS reduces exposure to certain carcinogens, it is not risk-free. The long-term health effects are still unknown, and critics argue that the product may simply shift the risk rather than eliminate it.
Regulatory Landscape
IQOS occupies a gray area in tobacco regulation. In some countries, it is classified as a tobacco product and subject to similar restrictions as cigarettes. In others, it falls under electronic nicotine delivery systems (ENDS), like e-cigarettes, and faces different rules.
The U.S. Food and Drug Administration (FDA) authorized the marketing of IQOS as a “modified risk tobacco product” in 2020, allowing Philip Morris to claim reduced exposure to harmful chemicals. However, the FDA emphasized that this does not mean IQOS is safe or approved for cessation.
Consumer Behavior and Appeal
IQOS appeals to a wide range of consumers, from tech-savvy smokers to those seeking a less intrusive way to consume nicotine. Its sleek design, minimal odor, and reduced ash make it attractive for indoor use and social settings. Some users report that switching to IQOS helps them reduce cigarette consumption, though complete cessation is rare without additional support.
Critics warn that the product may attract non-smokers, especially young adults, due to its modern aesthetic and perceived safety. This raises concerns about nicotine addiction and gateway behavior.
Environmental Considerations
While IQOS eliminates cigarette butts and reduces smoke pollution, it introduces new environmental challenges. The device requires electricity to charge, and the disposable HeatSticks generate waste. Recycling programs are limited, and the long-term ecological footprint of HNB products remains under study.
Conclusion
IQOS represents a significant shift in tobacco consumption, blending technology with nicotine delivery in a way that appeals to modern consumers. While it may reduce exposure to certain harmful substances, it is not without risks. As research continues and regulations evolve, the future of IQOS will depend on how well it balances innovation with public health priorities.
二、
